Tag: non-small cell lung cancer

FDA approves first chemotherapy and immunotherapy combination for non-small cell lung cancer

The FDA recently granted accelerated approval for pembrolizumab in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-small cell lung cancer (non-squamous). This is the first approval to combine immunotherapy with chemotherapy in lung cancer.  The trial compared standard chemotherapy to pembrolizumab along with standard chemotherapy in patients that… Read more »


Immunotherapy now approved as front-line treatment for certain subset of patients with non-small cell lung cancer

The KEYNOTE-024 trial was recently published that will be a game-changer for the first-line treatment of metastatic non-small cell lung cancer. In a certain subset of patients with PD-L1 expression over 50% (PD-L1 is a marker of immune activity within the tumor), patients were randomized to receive either standard chemotherapy or pembrolizumab (an immune therapy… Read more »